BioSpace News Archive

ABVC Biopharma, Inc., a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS), and ophthalmology, today announced its unaudited financial and operating results for the three-month period ended June 30, 2021.

NANO-X IMAGING LTD announced today that the Company will host a Business Update Video Presentation on Monday, August 16th at 8:30 am ET with Ran Poliakine, Chairman and Chief Executive Officer and other members of Nanox’s senior leadership.

DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced a new study at the American Association of Diabetes Care and Education Specialists (ADCES) annual conference demonstrating the impact of Dario’s intelligent personalization platform.

9 Meters Biopharma, Inc. today provided an overview of its recent achievements and reported financial results for the second quarter ended June 30, 2021.

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of Revixia Life Sciences, a wholly owned subsidiary developing Salvinorin A to treat a variety of mental health disorders.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Rosemary A. Crane to its Board of Directors.

CooperCompanies, announced that the Chinese National Medical Products Administration, which regulates medical devices and pharmaceuticals in China, has approved CooperVision MiSight® 1 day contact lenses for use within the country following a priority review.

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided additional information regarding the status of its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897).

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its second quarter ended June 30, 2021.

Fact.MR – A Market Research and Competitive Intelligence Provider: In its upcoming report, Fact.MR projects steady demand for global home respiratory therapy.